Observational studyBMC public health2025
WSK-V102C COVID-19 vaccine effectiveness against SARS-CoV-2 JN.1 symptomatic infection among adults 60 years and older: a prospective observational cohort study in Shaanxi Province, China, 2024.
Observational study in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundWSK-V102C is a trimeric recombinant protein COVID-19 vaccine against XBB1.5/BA.5/Delta variants that was approved for emergency use in China in June 2023. We evaluated WSK-V102C vaccine effectiveness (VE) against SARS CoV-2 JN.1 symptomatic infection among adults aged ≥ 60 years using an observational prospective cohort study.
methodsParticipants were recruited in Xixian New Area, Shaanxi Province in December 2023 and January 2024 and were offered the choice of vaccination or no vaccination. Vaccination was defined by receipt of one dose of WSK-V102C vaccine; follow-up was active, involving periodic PCR testing for infection - weekly for three months and every two weeks until the six-to-seven month follow-up was completed. The primary outcome of interest was laboratory-proven symptomatic SARS-CoV-2 infection. Cox proportional hazards regression modelling was used to estimate adjusted hazard ratios (aHR) for estimation of adjusted vaccine effectiveness (aVE), calculated as (1 - adjusted hazard ratio) multiplied by 100%, with 95% confidence intervals (CIs).
resultsAmong 6 313 participants meeting inclusion criteria, 3 216 received WSK-V102C and 3 097 did not receive WSK-V102C (or other COVID-19 vaccine) during the study period. The mean (SD) age of participants was 69.6 (6.4) years; the median follow-up time was 160 (IQR 153-166) days; 140 (2.2%) participants tested positive for SARS-CoV-2 nucleic acid, with 63 having symptomatic infection. No infected subjects were hospitalized or died. For prevention of symptomatic SARS-CoV-2 infection, all-ages aVE was 42.0% (95%CI: 3.5%, 65.1%); in 60-74-year-olds aVE was 50.1% (95%CI: 8.8%, 72.7%); and in individuals 75 years old and above, aVE was 10.6% (95%CI: -139.0%, 66.6%). Duration of symptoms was longer in unvaccinated subjects. Rates of laboratory-proven infection, including asymptomatic infection, were not different by vaccination status.
conclusionsAmong individuals aged ≥ 60 years, WSK-V102C vaccination provided moderate protection against JN.1 symptomatic infection within 6 months, suggesting that older people can benefit from use of this vaccine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.